公司服务主要涵盖生物医药早期成药性评价、非临床研究以及临床检测及转化研究三大板块，其中非临床研究板块具体包括非临床安全性评价、非临床药代动力学研究、非临床药效学研究。On August 23, Yinosi (688710.SH) started the subscription with an issue price of 19.06 yuan per share and a subscription limit of 0.008 million shares, with a P/E ratio of 15.4 times. It belongs to the STAR Market of the Shanghai Stock Exchange, and Haitong Securities is the sponsor and lead underwriter.
According to the Zhitong Finance app, on August 23, Yinosi (688710.SH) started the subscription with an issue price of 19.06 yuan per share and a subscription limit of 0.008 million shares, with a P/E ratio of 15.4 times. It belongs to the STAR Market of the Shanghai Stock Exchange, and Haitong Securities is the sponsor and lead underwriter.
The prospectus shows that Yinosi is a comprehensive research and development service (CRO) company that specializes in providing non-clinical research services for biopharmaceuticals, with GLP certification from NMPA, OECD, and the US FDA. It has competitive global service capabilities that comply with domestic and international standards, providing comprehensive new drug research services that meet domestic and international application standards for global pharmaceutical companies and research institutions.
The company's services mainly cover three major sectors: early evaluation of biomedical drugs, non-clinical research, and clinical testing, and translational research. The non-clinical research sector includes non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacological research.
After years of development and accumulation, Yinosi ranks among the top three in the domestic non-clinical safety evaluation segment, holding a leading position in the industry. As of December 31, 2023, Yinosi has nearly 0.06 million square meters of modern facilities and a highly skilled and comprehensive research team. During the reporting period, over 90% of Yinosi's annual revenue came from non-clinical research services for class I innovative drugs, and it has completed research services for several international and domestic first-innovative drugs for clients.
Since its establishment, Yinosi has gradually developed important core technologies such as toxicological biomarker assessment of major target organs, key technologies for special toxicological safety assessment, non-clinical safety evaluation system for innovative drugs, special drug administration technology for experimental animals, and platforms for the bioanalysis of small nucleic acids, peptides, ADCs, CGTs, high-sensitivity large molecule multi-antibody analysis, and flow cytometry receptor occupancy analysis.
The total amount of funds raised after deducting the issuance expenses is proposed to be used for the following investment projects:
In terms of finances, in 2021, 2022, and 2023, InnoThink's revenue was approximately RMB 0.582 billion, 0.863 billion, and 1.038 billion, respectively, with net income for the period approximately 84.5201 million, 0.118 billion, and 0.182 billion, respectively.
